Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736747 | 0.74 | ALOX15 (0.46) | KMT2AGRM5TSHRHDAC1HDAC6 | |
| SCHEMBL9147970 | 0.71 | TSHR (0.58) | KMT2AGRM5TSHRHDAC1HDAC6 | |
| SCHEMBL23882024 | 0.71 | TUBB4A (0.52) | KMT2ATSHRALDH1A1MAPT | |
| SCHEMBL20551422 | 0.70 | TSHR (0.50) | KMT2AGRM5TSHRHDAC1HDAC6 | |
| SCHEMBL12405541 | 0.69 | GRM5 (0.47) | KMT2AGRM5TSHRHDAC1HDAC6 | |
| SCHEMBL20553725 | 0.69 | TSHR (0.46) | KMT2AGRM5TSHRHDAC1HDAC6 | |
| SCHEMBL8204782 | 0.69 | KMT2A (0.42) | KMT2AGRM5TSHRHDAC1HDAC6 | |
| SCHEMBL3526671 | 0.68 | GRM5 (0.46) | KMT2AGRM5TSHRHDAC1HDAC6 | |
| SCHEMBL8209200 | 0.68 | TAAR1 (0.61) | KMT2AGRM5TSHR | |
| SCHEMBL1555164 | 0.68 | KMT2A (0.55) | KMT2AGRM5TSHRPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | P2RY1, P2RX1, P2RX3 | KMT2A 3531/4885GRM5 568/4885TSHR 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.